Both bariatric surgery and GLP-1 drugs cause mostly fat loss with moderate lean mass loss, and both improve the lean-to-fat ratio — but surgery produces roughly 2.5 times more fat loss over 24 months.
3.3% lean mass lossGLP-1RA patients lost only 3.3% of their lean mass while losing 18% of their fat mass over 24 months — meaning the vast majority of weight lost was fat, not muscle
What the researchers found
Over 24 months, both bariatric surgery and GLP-1 drugs (semaglutide/tirzepatide) produced substantial fat loss and moderate lean mass loss, but surgery was dramatically more effective. Surgery patients lost 49.7% of their fat mass versus 18.0% for GLP-1RA patients at 24 months. Lean mass loss was 11.7% with surgery versus 3.3% with GLP-1 drugs. Crucially, both groups improved their lean-to-fat ratio — meaning the weight lost was predominantly fat, not muscle. The lean-to-fat ratio improved to 2.0 with surgery and 1.5 with GLP-1 drugs at 24 months. Men preserved lean mass better than women, especially on GLP-1 drugs.
Why it matters
One of the biggest concerns about GLP-1 weight-loss drugs is that they cause excessive muscle loss ("Ozempic body"). This large real-world study provides reassuring data: while both surgery and GLP-1 drugs do cause some lean mass loss, the ratio of fat-to-lean mass lost is favorable in both cases. The lean-to-fat ratio actually improved, meaning patients became proportionally leaner. This is the largest real-world body composition comparison between bariatric surgery and modern GLP-1 drugs.
The numbers in context
n=3,066 · Surgery: 49.7% fat loss, 11.7% FFM loss at 24mo · GLP-1RA: 18.0% fat loss, 3.3% FFM loss at 24mo · FFM:FM ratio improved in both groups · Surgery FFM:FM 2.0 vs GLP-1RA 1.5 at 24mo · Men preserved more lean mass than women
How the study worked
Retrospective cohort study using electronic health records from Vanderbilt University Medical Center. 1,257 bariatric surgery patients and 1,809 GLP-1RA patients (semaglutide or tirzepatide) were followed for up to 24 months. Body composition was measured by bioelectrical impedance analysis at 2+ timepoints. Results were adjusted for age, sex, race, baseline BMI, diabetes status, treatment year, and time.
Who was studied
3,066 adults aged 18-65 with obesity: 1,257 bariatric surgery patients (mean BMI 46.8) and 1,809 GLP-1RA patients (mean BMI 41.0), ~80% women
What this study cannot tell us
This is a retrospective observational study, not a randomized trial — the surgery and GLP-1RA groups differed in baseline characteristics (surgery patients had higher mean BMI: 46.8 vs 41.0). Single-center data from Vanderbilt may not generalize to all populations. Bioelectrical impedance analysis is less precise than DEXA for measuring body composition. The GLP-1RA group included both semaglutide and tirzepatide, which may have different body composition effects.
How to read the evidence
This is a large retrospective cohort study (n=3,066) published in JAMA Network Open, a high-impact journal. It uses real-world clinical data with appropriate statistical adjustments. However, it's observational rather than randomized, and the groups were not directly comparable at baseline.
When this study was published
Published in 2026, this is one of the most current and largest real-world body composition analyses comparing GLP-1 drugs to bariatric surgery, using data through 2023.
The bigger picture
The "Ozempic body" concern — that GLP-1 drugs cause disproportionate muscle loss — has been a persistent media narrative. This large real-world study suggests the concern is somewhat overblown: while lean mass loss does occur, it's proportionally small compared to fat loss, and the overall body composition improves. However, the study also highlights that surgery still vastly outperforms drugs in terms of total fat reduction, which is important context for patients choosing between approaches.
Questions still open
- Would adding resistance training to GLP-1RA treatment further reduce lean mass loss and improve outcomes?
- Do semaglutide and tirzepatide differ in their effects on lean mass preservation?
- What explains the sex difference in lean mass preservation — is it hormonal, or related to baseline muscle mass?
Common questions
Do you lose more muscle than fat on Ozempic or Mounjaro?
How does weight loss on GLP-1 drugs compare to bariatric surgery?
Read the original research
Body Composition Changes After Bariatric Surgery or Treatment With GLP-1 Receptor Agonists.
JAMA network open, 9(1), e2553323
Citation
Wang, Zicheng; Wang, Lei; Zhang, Xinmeng; Lowery, Brandon D; Shaffer, Lauren Lee; Chen, You; Wells, Quinn S; Flynn, Charles R; Williams, Brandon; Spann, Matthew; Srivastava, Gitanjali; Samuels, Jason M; Yu, Danxia. (2026). Body Composition Changes After Bariatric Surgery or Treatment With GLP-1 Receptor Agonists.. JAMA network open, 9(1), e2553323. https://doi.org/10.1001/jamanetworkopen.2025.53323